导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.99% | 2695/4773 |
| 近一周 | -1.89% | 3083/5465 |
| 近一月 | -3.62% | 2692/5421 |
| 近一季 | -6.72% | 2524/5231 |
| 近半年 | -1.99% | 1979/4920 |
| 近一年 | 1.75% | 2420/4394 |
| 近两年 | 48.53% | 1552/2954 |
| 近三年 | 29.62% | 1101/2253 |
| 成立以来 | 77.59% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.78% 3411/4961 |
12.77% 2121/5312 |
- - |
- - |
| 2025 | 20.27% 2136/4813 |
-1.11% 2585/3635 |
2.21% 1764/4076 |
18.85% 2238/4524 |
0.13% 2191/4813 |
| 2024 | 17.45% 686/3463 |
2.99% 639/2808 |
-1.16% 959/3014 |
17.67% 1149/3129 |
-1.94% 1895/3463 |
| 2023 | -9.39% 1158/2656 |
4.50% 936/2280 |
-4.12% 1058/2385 |
-2.93% 793/2515 |
-6.85% 1944/2655 |
| 2022 | -20.09% 931/2207 |
-14.44% 946/1919 |
7.00% 552/2016 |
-14.26% 1054/2113 |
1.81% 1130/2208 |
| 2021 | -2.38% 853/1822 |
-3.01% 741/1255 |
4.69% 856/1330 |
-5.61% 832/1466 |
1.86% 775/1822 |
| 2020 | 31.02% 509/1250 |
-9.81% 720/1028 |
13.96% 580/1067 |
11.89% 418/1164 |
13.93% 321/1184 |
| 2019 | 38.64% 304/1092 |
28.03% 328/754 |
0.10% 199/804 |
0.92% 444/850 |
7.20% 470/918 |
| 2018 | -23.35% 277/834 |
- - |
- - |
- - |
-12.15% 412/691 |
| 2017 | 23.79% 129/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.57% 222/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发沪深300ETF VS. 长安沪深300非周期A(740101) |